Trefoil Therapeutics Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Series A2
- Latest Deal Amount
-
$4.56M
- Investors
-
12
Trefoil Therapeutics General Information
Description
Developer of corneal therapeutics designed to facilitate the treatment of ophthalmic diseases. The company's therapy is focused on leveraging its engineered fibroblast growth factor-one protein technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases and help regenerate the endothelial cell layer and eliminate the symptoms associated with this condition that leads to the loss of vision, enabling ophthalmologists to treat patients with severe corneal endothelial diseases and epithelial disorders.
Contact Information
Website
www.trefoiltherapeutics.comCorporate Office
- 6330 Nancy Ridge Drive
- Suite 103
- San Diego, CA 92121
- United States
Corporate Office
- 6330 Nancy Ridge Drive
- Suite 103
- San Diego, CA 92121
- United States
Trefoil Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series A2) | 06-May-2025 | $4.56M | Completed | Clinical Trials - Phase 2 | ||
| 5. Later Stage VC (Series A1) | 22-Mar-2022 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series A) | 05-Aug-2019 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series 1) | 05-Jan-2017 | Completed | Startup | |||
| 2. Grant | 20-Oct-2015 | Completed | Startup | |||
| 1. Accelerator/Incubator | 01-Jan-2013 | Completed | Startup |
Trefoil Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Trefoil Therapeutics Comparisons
Industry
Financing
Details
Trefoil Therapeutics Competitors (92)
One of Trefoil Therapeutics’s 92 competitors is Casma Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Casma Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Alentis Therapeutics | Venture Capital-Backed | Allschwil, Switzerland | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Immusoft | Venture Capital-Backed | Seattle, WA |
Trefoil Therapeutics Patents
Trefoil Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024247068-A1 | Recombinant modified fibroblast growth factors and therapeutic uses thereof | Pending | 28-Mar-2023 | ||
| EP-4687945-A2 | Recombinant modified fibroblast growth factors and therapeutic uses thereof | Pending | 28-Mar-2023 | ||
| US-20260265323-A1 | Recombinant modified fibroblast growth factors and therapeutic uses thereof | Pending | 28-Mar-2023 | ||
| WO-2024206358-A2 | Recombinant modified fibroblast growth factors and therapeutic uses thereof | Inactive | 28-Mar-2023 | ||
| WO-2024206358-A3 | Recombinant modified fibroblast growth factors and therapeutic uses thereof | Inactive | 28-Mar-2023 | A61K38/1825 |
Trefoil Therapeutics Signals
Trefoil Therapeutics Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Solasta Ventures | Venture Capital | Minority | ||
| Access Biotechnology | Corporate Venture Capital | Minority | ||
| Bios Partners | Venture Capital | Minority | ||
| FemHealth Ventures | Venture Capital | Minority | ||
| AJU IB Investment | Venture Capital | Minority |
Trefoil Therapeutics FAQs
-
When was Trefoil Therapeutics founded?
Trefoil Therapeutics was founded in 2013.
-
Where is Trefoil Therapeutics headquartered?
Trefoil Therapeutics is headquartered in San Diego, CA.
-
What is the size of Trefoil Therapeutics?
Trefoil Therapeutics has 10 total employees.
-
What industry is Trefoil Therapeutics in?
Trefoil Therapeutics’s primary industry is Drug Discovery.
-
Is Trefoil Therapeutics a private or public company?
Trefoil Therapeutics is a Private company.
-
What is the current valuation of Trefoil Therapeutics?
The current valuation of Trefoil Therapeutics is .
-
What is Trefoil Therapeutics’s current revenue?
The current revenue for Trefoil Therapeutics is .
-
How much funding has Trefoil Therapeutics raised over time?
Trefoil Therapeutics has raised $49.7M.
-
Who are Trefoil Therapeutics’s investors?
Solasta Ventures, Access Biotechnology, Bios Partners, FemHealth Ventures, and AJU IB Investment are 5 of 12 investors who have invested in Trefoil Therapeutics.
-
Who are Trefoil Therapeutics’s competitors?
Casma Therapeutics, Alentis Therapeutics, Cognition Therapeutics, Inovio Pharmaceuticals, and Immusoft are some of the 92 competitors of Trefoil Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process